SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1SXP - DE000A3ENQ51 - Common Stock
15.42 EUR
+0.12 (+0.78%)
Taking everything into account, 1SXP scores 6 out of 10 in our fundamental rating. 1SXP was compared to 22 industry peers in the Life Sciences Tools & Services industry. 1SXP has an excellent profitability rating, but there are some minor concerns on its financial health. 1SXP has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
1SXP had positive earnings in the past year.
In the past year 1SXP had a positive cash flow from operations.
In the past 5 years 1SXP has always been profitable.
Each year in the past 5 years 1SXP had a positive operating cash flow.
1.2 Ratios
1SXP has a better Return On Assets (9.16%) than 81.82% of its industry peers.
1SXP's Return On Equity of 16.42% is amongst the best of the industry. 1SXP outperforms 86.36% of its industry peers.
1SXP's Return On Invested Capital of 13.06% is amongst the best of the industry. 1SXP outperforms 86.36% of its industry peers.
1SXP had an Average Return On Invested Capital over the past 3 years of 14.59%. This is significantly above the industry average of 9.06%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 16.42% | ||
| ROIC | 13.06% |
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1.3 Margins
With a decent Profit Margin value of 14.85%, 1SXP is doing good in the industry, outperforming 72.73% of the companies in the same industry.
In the last couple of years the Profit Margin of 1SXP has grown nicely.
1SXP has a Operating Margin of 18.95%. This is in the better half of the industry: 1SXP outperforms 77.27% of its industry peers.
1SXP's Operating Margin has improved in the last couple of years.
1SXP's Gross Margin of 33.71% is on the low side compared to the rest of the industry. 1SXP is outperformed by 68.18% of its industry peers.
1SXP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.95% | ||
| PM (TTM) | 14.85% | ||
| GM | 33.71% |
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
2. Health
2.1 Basic Checks
1SXP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for 1SXP remains at a similar level compared to 1 year ago.
Compared to 5 years ago, 1SXP has about the same amount of shares outstanding.
Compared to 1 year ago, 1SXP has an improved debt to assets ratio.
2.2 Solvency
1SXP has a debt to FCF ratio of 2.43. This is a good value and a sign of high solvency as 1SXP would need 2.43 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 2.43, 1SXP belongs to the best of the industry, outperforming 86.36% of the companies in the same industry.
1SXP has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
1SXP has a Debt to Equity ratio of 0.09. This is amongst the best in the industry. 1SXP outperforms 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | N/A |
ROIC/WACC1.44
WACC9.05%
2.3 Liquidity
1SXP has a Current Ratio of 1.50. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
1SXP has a Current ratio of 1.50. This is in the better half of the industry: 1SXP outperforms 63.64% of its industry peers.
1SXP has a Quick Ratio of 1.12. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
1SXP's Quick ratio of 1.12 is fine compared to the rest of the industry. 1SXP outperforms 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
The earnings per share for 1SXP have decreased by -2.02% in the last year.
The Earnings Per Share has been growing by 13.78% on average over the past years. This is quite good.
Looking at the last year, 1SXP shows a small growth in Revenue. The Revenue has grown by 3.04% in the last year.
The Revenue has been growing by 11.04% on average over the past years. This is quite good.
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
3.2 Future
1SXP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.98% yearly.
1SXP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.13% yearly.
EPS Next Y5.75%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
EPS Next 5Y12.98%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y7.13%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 15.90, 1SXP is valued correctly.
90.91% of the companies in the same industry are more expensive than 1SXP, based on the Price/Earnings ratio.
1SXP is valuated rather cheaply when we compare the Price/Earnings ratio to 27.19, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 15.03 indicates a correct valuation of 1SXP.
1SXP's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1SXP is cheaper than 90.91% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.92. 1SXP is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.9 | ||
| Fwd PE | 15.03 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1SXP is valued cheaper than 90.91% of the companies in the same industry.
63.64% of the companies in the same industry are cheaper than 1SXP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 66.05 | ||
| EV/EBITDA | 8.87 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
1SXP has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.77
PEG (5Y)1.15
EPS Next 2Y11.1%
EPS Next 3Y11.63%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.18%, 1SXP has a reasonable but not impressive dividend return.
In the last 3 months the price of 1SXP has falen by -24.41%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.54. 1SXP pays more dividend than 90.91% of the companies in the same industry.
1SXP's Dividend Yield is slightly below the S&P500 average, which is at 1.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.18% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
16.45% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.45%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
FRA:1SXP (1/9/2026, 7:00:00 PM)
15.42
+0.12 (+0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners22.72%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.32B
Revenue(TTM)986.21M
Net Income(TTM)146.45M
Analysts75.79
Price Target23.9 (54.99%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.18% |
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP16.45%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.27%
Min EPS beat(2)-3.5%
Max EPS beat(2)-1.05%
EPS beat(4)1
Avg EPS beat(4)-3.37%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)3
Avg EPS beat(8)1.1%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.13%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)-1.99%
Revenue beat(4)1
Avg Revenue beat(4)-1.96%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.41%
PT rev (3m)-20.68%
EPS NQ rev (1m)-6.61%
EPS NQ rev (3m)-14.29%
EPS NY rev (1m)-10.89%
EPS NY rev (3m)-15.27%
Revenue NQ rev (1m)-3.21%
Revenue NQ rev (3m)-5.48%
Revenue NY rev (1m)-4.21%
Revenue NY rev (3m)-5.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.9 | ||
| Fwd PE | 15.03 | ||
| P/S | 2.35 | ||
| P/FCF | 66.05 | ||
| P/OCF | 12.91 | ||
| P/B | 2.6 | ||
| P/tB | 2.69 | ||
| EV/EBITDA | 8.87 |
EPS(TTM)0.97
EY6.29%
EPS(NY)1.03
Fwd EY6.65%
FCF(TTM)0.23
FCFY1.51%
OCF(TTM)1.19
OCFY7.75%
SpS6.55
BVpS5.92
TBVpS5.72
PEG (NY)2.77
PEG (5Y)1.15
Graham Number11.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 16.42% | ||
| ROCE | 16.33% | ||
| ROIC | 13.06% | ||
| ROICexc | 13.46% | ||
| ROICexgc | 13.83% | ||
| OM | 18.95% | ||
| PM (TTM) | 14.85% | ||
| GM | 33.71% | ||
| FCFM | 3.57% |
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
ROICexc(3y)15.01%
ROICexc(5y)16.12%
ROICexgc(3y)15.5%
ROICexgc(5y)16.82%
ROCE(3y)18.26%
ROCE(5y)19.44%
ROICexgc growth 3Y-6.05%
ROICexgc growth 5Y-8.67%
ROICexc growth 3Y-5.65%
ROICexc growth 5Y-7.55%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
F-Score6
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.43 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 182.22% | ||
| Cap/Sales | 14.68% | ||
| Interest Coverage | 11.84 | ||
| Cash Conversion | 67.54% | ||
| Profit Quality | 24.01% | ||
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | N/A |
F-Score6
WACC9.05%
ROIC/WACC1.44
Cap/Depr(3y)260.7%
Cap/Depr(5y)265.72%
Cap/Sales(3y)16.46%
Cap/Sales(5y)16.64%
Profit Quality(3y)27.05%
Profit Quality(5y)27.58%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
EPS Next Y5.75%
EPS Next 2Y11.1%
EPS Next 3Y11.63%
EPS Next 5Y12.98%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y7.13%
EBIT growth 1Y5.25%
EBIT growth 3Y3.6%
EBIT growth 5Y15.48%
EBIT Next Year43.48%
EBIT Next 3Y20.64%
EBIT Next 5Y16.53%
FCF growth 1Y-55.75%
FCF growth 3Y6.15%
FCF growth 5Y12.98%
OCF growth 1Y-19.95%
OCF growth 3Y-0.4%
OCF growth 5Y11.5%
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.
What is the valuation status for 1SXP stock?
ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
How profitable is SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 7 / 10.
Can you provide the financial health for 1SXP stock?
The financial health rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 6 / 10.
What is the earnings growth outlook for SCHOTT PHARMA AG& CO KGAA?
The Earnings per Share (EPS) of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is expected to grow by 5.75% in the next year.